Interleukin 17 (IL-17) sustains pancreatic ductal adenocarcinoma (PDAC) immunosuppression by reducing CD8+ T-cell recruitment and activation, and recruits neutrophils and stimulates NETs formation in pancreatic tumors via factors released from tumor cells. Here, IL17A is linked to pancreatic ductal adenocarcinoma.